Millions of Americans and Canadians are breathing bad air right now due to wildfire smoke. Here’s what you need to know masks ...

NicoBlox takes on the role of a nurse at a mysterious animal hospital where maintaining sanity is crucial for survival. As ...

Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 for the Treatment of Meniere’s Disease (MD). SPI-1005, a novel oral ...

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...

Kelun-Biotech, listed under stock code 6990.HK, announced its Phase III OptiTROP-Lung06 trial of sac-TMT combined with ...

Immutep and its investors are confident the company can salvage something from its cancelled lung cancer program.

Study examines Qalsody safety after approval “This study is the first to systematically conduct a post-marketing [safety] ...

Good day, everyone, and welcome to today's conference call to discuss the 12-month results from our ongoing open-label extension study of TPIP in patients with PAH. Before we start, please note that ...

In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.

AstraZeneca has secured exclusive global rights to Dizal's Zegfrovy (sunvozertinib) through a new licensing agreement.

From mattresses to saucepans, scientists offer tweaks to help detoxify your space ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and GI oncology diseases, today announced the ...